Comparative effectiveness among thromboprophylaxis strategies after the Fontan operation: A systematic review and network meta-analysis

IF 3.7 3区 医学 Q1 HEMATOLOGY Thrombosis research Pub Date : 2024-07-08 DOI:10.1016/j.thromres.2024.109093
Saviga Sethasathien , Phichayut Phinyo , Rekwan Sittiwangkul , Suchaya Silvilairat
{"title":"Comparative effectiveness among thromboprophylaxis strategies after the Fontan operation: A systematic review and network meta-analysis","authors":"Saviga Sethasathien ,&nbsp;Phichayut Phinyo ,&nbsp;Rekwan Sittiwangkul ,&nbsp;Suchaya Silvilairat","doi":"10.1016/j.thromres.2024.109093","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>A variety of thromboprophylaxis regimens have been administered in patients following the Fontan procedure. However, consensus guidelines regarding the optimal thromboprophylaxis strategy have not yet been developed.</p></div><div><h3>Method</h3><p>A network meta-analysis was conducted to evaluate the comparative effectiveness among available thromboprophylaxis regimens and major bleeding events associated with these regimens.</p></div><div><h3>Results</h3><p>A total of 28 comparative studies with 4430 Fontan patients were included. The incidence of thromboembolic events (TE) was significantly lower in individuals who underwent thromboprophylaxis compared to those who did not. Compared to a no-treatment strategy, nonvitamin K oral anticoagulants (NOACs) showed the largest treatment effect for preventing TE (OR = 0.08, 95 % CI 0.03 to 0.21), followed by warfarin (OR = 0.16, 95 % CI 0.10 to 0.27), and aspirin (OR = 0.23, 95 % CI 0.14 to 0.38). Indeed, NOACs were significantly more effective than aspirin in preventing TE (OR = 0.35, 95 % CI 0.14 to 0.84). Aspirin was associated with the lowest occurrence of major bleeding events, followed by NOACs, no medication, and warfarin. NOACs were shown to possess a highly favorable overall profile.</p></div><div><h3>Conclusion</h3><p>Prescribing thromboprophylaxis drugs, either antiplatelets or anticoagulants, may be more effective in preventing TE after the Fontan operation than not doing so. Among the included regimens, NOACs demonstrated significantly greater efficacy than aspirin; however, they did not show statistically significant superiority over warfarin. Aspirin exhibited lower rates of major bleeding compared to both NOACs and warfarin. Overall, NOACs tended to offer the most advantageous balance of efficacy and safety. However, the findings should be interpreted considering the certainty and limitations of the evidence, including potential residual confounding in observational studies.</p></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049384824002251","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

A variety of thromboprophylaxis regimens have been administered in patients following the Fontan procedure. However, consensus guidelines regarding the optimal thromboprophylaxis strategy have not yet been developed.

Method

A network meta-analysis was conducted to evaluate the comparative effectiveness among available thromboprophylaxis regimens and major bleeding events associated with these regimens.

Results

A total of 28 comparative studies with 4430 Fontan patients were included. The incidence of thromboembolic events (TE) was significantly lower in individuals who underwent thromboprophylaxis compared to those who did not. Compared to a no-treatment strategy, nonvitamin K oral anticoagulants (NOACs) showed the largest treatment effect for preventing TE (OR = 0.08, 95 % CI 0.03 to 0.21), followed by warfarin (OR = 0.16, 95 % CI 0.10 to 0.27), and aspirin (OR = 0.23, 95 % CI 0.14 to 0.38). Indeed, NOACs were significantly more effective than aspirin in preventing TE (OR = 0.35, 95 % CI 0.14 to 0.84). Aspirin was associated with the lowest occurrence of major bleeding events, followed by NOACs, no medication, and warfarin. NOACs were shown to possess a highly favorable overall profile.

Conclusion

Prescribing thromboprophylaxis drugs, either antiplatelets or anticoagulants, may be more effective in preventing TE after the Fontan operation than not doing so. Among the included regimens, NOACs demonstrated significantly greater efficacy than aspirin; however, they did not show statistically significant superiority over warfarin. Aspirin exhibited lower rates of major bleeding compared to both NOACs and warfarin. Overall, NOACs tended to offer the most advantageous balance of efficacy and safety. However, the findings should be interpreted considering the certainty and limitations of the evidence, including potential residual confounding in observational studies.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
方坦手术后血栓预防策略的有效性比较:系统回顾和网络荟萃分析
导言:目前已对接受丰坦手术的患者实施了多种血栓预防方案。方法 进行了一项网络荟萃分析,以评估现有血栓预防方案的有效性比较以及与这些方案相关的大出血事件。结果 共纳入28项比较研究,4430名Fontan患者。与未采取血栓预防措施的患者相比,采取血栓预防措施的患者血栓栓塞事件(TE)发生率明显较低。与不采取治疗策略相比,非维生素K口服抗凝药(NOACs)对预防血栓栓塞事件的治疗效果最好(OR = 0.08,95 % CI 0.03 至 0.21),其次是华法林(OR = 0.16,95 % CI 0.10 至 0.27)和阿司匹林(OR = 0.23,95 % CI 0.14 至 0.38)。事实上,NOAC 在预防 TE 方面的效果明显优于阿司匹林(OR = 0.35,95 % CI 0.14 至 0.84)。阿司匹林的大出血事件发生率最低,其次是 NOACs、不用药和华法林。结论在丰坦手术后使用抗血小板或抗凝药物预防血栓形成可能比不使用更有效。在纳入的治疗方案中,NOACs的疗效明显优于阿司匹林;但在统计学上,NOACs与华法林相比并无明显优势。与 NOACs 和华法林相比,阿司匹林的大出血率较低。总体而言,NOAC 在疗效和安全性之间的平衡最具优势。不过,在解释研究结果时应考虑到证据的确定性和局限性,包括观察性研究中可能存在的残余混杂因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Thrombosis research
Thrombosis research 医学-外周血管病
CiteScore
14.60
自引率
4.00%
发文量
364
审稿时长
31 days
期刊介绍: Thrombosis Research is an international journal dedicated to the swift dissemination of new information on thrombosis, hemostasis, and vascular biology, aimed at advancing both science and clinical care. The journal publishes peer-reviewed original research, reviews, editorials, opinions, and critiques, covering both basic and clinical studies. Priority is given to research that promises novel approaches in the diagnosis, therapy, prognosis, and prevention of thrombotic and hemorrhagic diseases.
期刊最新文献
The role of anticoagulation on the long-term survival of patients with pulmonary arterial hypertension: A meta-analysis of 15 cohort studies. Hemophilia A: Economic burden, therapeutic advances, and future forecasts in the Middle East and North Africa region. Limitations of a platelet count-based clinical decision support system to facilitate diagnosis of heparin-induced thrombocytopenia Prothrombin complex concentrate for direct factor Xa inhibitor-associated bleeding or before urgent surgery. COVID-19 venous thromboembolism prophylaxis guidelines in pediatrics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1